| about us | our approach | our expertise | solutions | case studies | clients | news & events | contact | careers |
| |
|
 |
 |
|
|
| News & events |
|
5 June 2003 Event Round-up techMARK mediscience awards dinner, 5 June 2003, Hotel Intercontinental, London Katja Stout and Caroline Stupnicka attended the techMARK mediscience awards dinner as guests of Northbank's client Oxford BioMedica. The event, sponsored by the London Stock Exchange and Evolution Beeson Gregory, was attended by over 400 guests including: techMARK mediscience companies, corporate brokers, lawyers, fund managers, analysts, accountants, PR consultants and journalists. The awards form part of an ongoing programme of activities to maintain focus on and raise visibility of techMARK mediscience companies - the first international market for healthcare companies launched by the London Stock Exchange in 2001. The winners on the day were:
Northbank Communications would like to congratulate all the winners on their awards. Biotechnology Investment Today Conference, 5 June 2003, London - Northbank sponsors Biotechnology Investment Today Conference Northbank was sponsors of the Biotechnology Investment Today (BIT) 2003 CEO BioBusiness Seminar and Investor conference on 5 June. The day consisted of informative panel discussions and Q&As chaired by Paul Wake, former Editor-in-Chief of BIT at the scenic offices on the top floor of the London Stock Exchange Building, with breath taking vistas of the City of London. The day kicked off with Q&A discussions from Rachel Maguire, Head of Issuer Services, LSE and William Powlett Smith, Head of Health Sciences Group, E&Y. Sue Charles, CEO at Northbank, participated in a panel discussion on Public Relations vs Investor Relations, focused on managing shareholder expectations and how a private company should prepare for a listing. Other panel discussions included discussions around the financing of European biotechs and drew conclusions that there was a lot of untapped money in Switzerland as well as in Asia, provided that you had the right advisors in the latter continent. The atmosphere was one of cautious optimism, fuelled by news of the successful close of the third international Schroder Ventures Life Sciences Fund at just over $400m, which was announced by Northbank Communications (press release) and the 30 – 40% rise in biotech market indices over the previous months. The wrap-up consisted of a summary of the E&Y report, Endurance, by William Powlett Smith. Despite bleak financing conditions and a 60% increase in companies with less than one year of cash, positive trends have included a marked increase of VC funding going into biotechnology, genomics in particular, and in products progressing through clinical trials. Fundamentals for the latter half of 2003 were predicted to be positive. BIO2003, 22 – 25 June 2003, Washington If you tap the biotech barometer at the moment the needle is moving towards fair. In the last three months BioCentury's BC 100 Index has risen a reassuring 40% (39.5%). The improving temperature was perceptible at the recent BioIndustry Organisation convention in Washington. BIO was ‘seriously buzzy' says UK BioScience Managers' Jeremy Curnock Cook, who is raising money for a new biotech fund. ‘It's fascinating how different the US is to the UK. Once they get the bit between their teeth they just go from glacial to lava. In that week companies were seeing exceptional share price hikes on the back of new clinical data and companies were suddenly raising money where previously none was forthcoming. Many of Northbank's clients had a presence at the annual industry event. Commenting on the event Dr Zisi Fotev VP Business Development from atugen, Berlin, had a stand there. "I wouldn't say the level of the presentations was that cutting edge or that the poster sessions were that well attended but, as ever, the main reason for going there is that you just meet everybody. We met our Japanese clients and most of our other partners." And this year, even George W Bush turned up. We're all interested in biotechnology. ChemSpec 4-5 June, Manchester, UK Nicola Reed Jones from Northbank Communications joined over 2,600 visitors browsing around 273 exhibitor companies this year, which drew in record attendance. The ChemSpec Europe exhibition is focused on the needs of the fine and speciality chemicals market, which in turn serves a diverse marketplace. In spite of animal cruelty activists, concerns over SARS and the strike by French air traffic controllers, the event was well attended from companies worldwide, with the greatest number of exhibitors coming from UK, Germany, China and India respectively. Focus 2003, 13 – 15 May 2003, Manchester "Our aims are to ensure that diagnostics no longer remains a ‘best kept secret' and to begin the process to ensure that UK plc's investment in diagnostics no longer stays as second lowest amongst our EC partner countries", proclaimed Gilbert Wieringa, Chair of Focus 2003, the national meeting of the Association of Clinical Biochemists (ABI). A bold statement, but one that this years Focus event, has done little to quell. Coinciding with the ABI's golden anniversary, the meeting attracted both established and new players in the diagnostics industry, with over 50 exhibitors including the likes of Roche, Bayer, Beckman Coulter and Abbott. Attended by Peter Colley and James Parkinson from Northbank's Manchester office, the event provided a platform to raise awareness of diagnostics to patients, the public and government, and was jointly organised with the British In Vitro Diagnostics Association (BIVDA). As well as a lively exhibition hall, the three-day programme squeezed in key speakers such as Dr S Hill, Chief Scientific Officer of the Department of Health, workshops and lectures, the ACB 50th Anniversary Banquet and culminated with the presentation of the Bayer Research Award. |
| © 2007 College Hill Associates | Registered in England No 1036926 / VAT No 245666930 | Legal |
|
News |
|
Events |
|
In the News |
|
Newsletters |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|